TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00146211|
Recruitment Status : Completed
First Posted : September 7, 2005
Last Update Posted : December 27, 2007
|Condition or disease||Intervention/treatment||Phase|
|Huntington Disease||Drug: Ethyl-EPA (Miraxion™)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease|
|Study Start Date :||September 2005|
|Actual Primary Completion Date :||August 2007|
|Actual Study Completion Date :||July 2007|
- To compare with placebo the effect of ethyl-EPA on the Total Motor Score-4 component (TMS) of the Unified Huntington's Disease Rating Scale (UHDRS) over a 6-month period of observation.
- To compare with placebo the effect of ethyl-EPA over a 6-month period of observation on, 1) Chorea (UHDRS Total Motor Score Scale); 2) Total Motor Score component (TMS) of the UHDRS; and, 3) Clinical Global Impression (CGI) score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00146211
|Principal Investigator:||Ira Shoulson, MD||Huntington Study Group/University of Rochester|
|Principal Investigator:||Christopher Ross, MD, PhD||Huntington Study Group/Johns Hopkins University School of Medicine|
|Principal Investigator:||Blair Leavitt, MD||Huntington Study Group/University of British Columbia|